<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK548183" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK548183/" /><meta name="ncbi_pagename" content="Ticarcillin-Clavulanate - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Ticarcillin-Clavulanate - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Ticarcillin-Clavulanate" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/10/20" /><meta name="citation_pmid" content="31643511" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK548183/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Ticarcillin-Clavulanate" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/10/20" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK548183/" /><meta name="description" content="The combination of ticarcillin and clavulanate provides an extended-spectrum penicillin with a beta-lactamase inhibitor and was previously used to treat serious bacterial infections due to susceptible organisms. Given parenterally, ticarcillin-clavulanate can cause mild transient aminotransferase elevations, and therapy has been linked to instances of acute cholestatic liver disease similar to that described commonly with amoxicillin-clavulanate (Augmentin)." /><meta name="og:title" content="Ticarcillin-Clavulanate" /><meta name="og:type" content="book" /><meta name="og:description" content="The combination of ticarcillin and clavulanate provides an extended-spectrum penicillin with a beta-lactamase inhibitor and was previously used to treat serious bacterial infections due to susceptible organisms. Given parenterally, ticarcillin-clavulanate can cause mild transient aminotransferase elevations, and therapy has been linked to instances of acute cholestatic liver disease similar to that described commonly with amoxicillin-clavulanate (Augmentin)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK548183/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/TicarcillinClavulana/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK548183/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8D857504690BC100000000011D0056.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK548183_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK548183_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ticarcillin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ticlopidine/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK548183_"><span class="title" itemprop="name">Ticarcillin-Clavulanate</span></h1><p class="small">Last Update: <span itemprop="dateModified">October 20, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><div id="TicarcillinClavulana.OVERVIEW"><h2 id="_TicarcillinClavulana_OVERVIEW_">OVERVIEW</h2><div id="TicarcillinClavulana.Introduction"><h3>Introduction</h3><p>The combination of ticarcillin and clavulanate provides an extended-spectrum penicillin with a beta-lactamase inhibitor and was previously used to treat serious bacterial infections due to susceptible organisms. Given parenterally, ticarcillin-clavulanate can cause mild transient aminotransferase elevations, and therapy has been linked to instances of acute cholestatic liver disease similar to that described commonly with amoxicillin-clavulanate (Augmentin).</p></div><div id="TicarcillinClavulana.Background"><h3>Background</h3><p>The combination of ticarcillin, a fourth generation penicillin, and clavulanate combines the extended-spectrum of ticarcillin with beta-lactamase inhibitory activity of clavulanic acid. Neither ticarcillin nor ticarcillin-clavulanate are commercially available in the United States, the combination having been withdrawn from the market in 2015. This combination was indicated for serious infections of the lower respiratory tract, urinary tract, bones and joints and skin. The extended-spectrum of ticarcillin made it an appropriate agent in therapy of Pseudomonas aeruginosa. Ticarcillin also has extended activity against some Enterobacter and Proteus. Ticarcillin is poorly absorbed by mouth and requires parenteral administration. The combination of ticarcillin and clavulanate was approved for use in the United States initially in 1985 under the trade name of Timentin. The combination was provided as 3 grams of ticarcillin with 100 mg of clavulanate which was typically given intravenously every 4 to 6 hours for 5 to 14 days. Common side effects of ticarcillin included nausea, epigastric discomfort, diarrhea, headache, dizziness, rash and hypersensitivity reactions. Rare but potentially serious adverse events included anaphylaxis, hypersensitivity syndrome, renal dysfunction and Stevens Johnson syndrome.</p></div><div id="TicarcillinClavulana.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Intravenous therapy with ticarcillin and clavulanate has been associated with elevations in serum aminotransferase levels in up to 10% of patients; however, these abnormalities were usually subclinical and self-limited. More important were rare instances of acute cholestatic liver injury arising several days to several weeks after initiation of ticarcillin-clavulanate. This hepatic injury resembled that caused by amoxicillin-clavulanate and was probably caused by the beta-lactamase inhibitor rather than the ticarcillin. However, too few cases were described in the literature to define the clinical characteristics of the idiosyncratic liver injury.</p><p>Likelihood score: D (possible rare cause of clinically apparent liver injury).</p></div><div id="TicarcillinClavulana.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The cause of the liver injury associated with the combination of ticarcillin and clavulanate was probably hypersensitivity to the clavulanic acid. However, the possibility exists that some instances of hepatotoxicity following this combination were due to ticarcillin.</p></div><div id="TicarcillinClavulana.Outcome_and_Managem"><h3>Outcome and Management</h3><p>In the few cases of cholestatic liver injury following therapy with ticarcillin-clavulanate that have been described, resolution occurred rapidly in one patient whereas the second died of an underlying disease before recovery was complete. Cases of fatalities and chronic cholestasis have been described after amoxicillin-clavulanate therapy which is a much more commonly prescribed combination.</p><p>Drug Class: Antiinfective Agents, <a href="/books/n/livertox/PenicillinFourthGen/">Penicillins (Fourth Generation)</a></p><p>Other Drugs in the Class: <a href="/books/n/livertox/Piperacillin/">Piperacillin</a>, <a href="/books/n/livertox/PiperacillinTazob/">Piperacillin-Tazobactam</a>, <a href="/books/n/livertox/Ticarcillin/">Ticarcillin</a></p></div></div><div id="TicarcillinClavulana.PRODUCT_INFORMATION"><h2 id="_TicarcillinClavulana_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Ticarcillin-Clavulanate &#x02013; Generic, Timentin&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antiinfective Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=ticarcillin+clavulanate" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a></p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="TicarcillinClavulana.CHEMICAL_FORMULA_AN"><h2 id="_TicarcillinClavulana_CHEMICAL_FORMULA_AN_">CHEMICAL FORMULA AND STRUCTURE</h2><div id="TicarcillinClavulana.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK548183/table/TicarcillinClavulana.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__TicarcillinClavulana.Tc_lrgtbl__"><table><thead><tr><th id="hd_h_TicarcillinClavulana.Tc_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_TicarcillinClavulana.Tc_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NO</th><th id="hd_h_TicarcillinClavulana.Tc_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_TicarcillinClavulana.Tc_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_TicarcillinClavulana.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Ticarcillin-<br /> Clavulanic Acid</td><td headers="hd_h_TicarcillinClavulana.Tc_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135061937" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">86482-18-0</a></td><td headers="hd_h_TicarcillinClavulana.Tc_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C15-H16-N2-O6-S2.<br /> C8-H9-N-O5</td><td headers="hd_h_TicarcillinClavulana.Tc_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135061937" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135061937" alt="image 135061937 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="TicarcillinClavulana.ANNOTATED_BIBLIOGRA"><h2 id="_TicarcillinClavulana_ANNOTATED_BIBLIOGRA_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 20 October 2020</p><ul class="first-line-outdent"><li><div class="bk_ref" id="TicarcillinClavulana.REF.zimmerman.1999">Zimmerman HJ. Penicillins. In, Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver. 2nd Ed. Philadelphia: Lippincott, 1999. p. 595-6.<div><i>(Expert review of penicillins and liver injury published in 1999; piperacillin and ticarcillin are listed as associated with elevations in aminotransferase levels, but without reports of clinically apparent liver injury except with ticarcillin-clavulanate).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.moseley.2013">Moseley RH. Hepatotoxicity of antimicrobials and antifungal agents. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 463-82.<div><i>(Expert review of penicillin induced liver injury mentions that there have been few reports of liver injury due to the extended-spectrum penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.macdougall.2018">MacDougall C. Penicillins, cephalosporins, and other &#x003b2;-lactam antibiotics. In, Brunton LL, Hilal-Dandan R, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 13th ed. New York: McGraw-Hill, 2018, pp. 1023-38.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.pines.1974.39">Pines A, Khaja G, Raafat H, Sreedharan KS. Preliminary clinical experience with ticarcillin (BRL 2288) in 101 patients treated for severe respiratory infection. <span><span class="ref-journal">Chemotherapy. </span>1974;<span class="ref-vol">20</span>:39–44.</span> [<a href="/pubmed/4210892" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4210892</span></a>]<div><i>(Early experience in 101 patients with severe infections given im ticarcillin; local pain was common; minimal and transient elevations in ALT occurred in 4 and Alk P in 5 patients).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.parry.1978.961">Parry MF, Neu HC. Comparative study of ticarcillin plus tobramycin versus carbenicillin plus gentamicin for the treatment of serious infections due to gram-negative bacilli. <span><span class="ref-journal">Am J Med. </span>1978;<span class="ref-vol">64</span>:961–6.</span> [<a href="/pubmed/247895" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 247895</span></a>]<div><i>(Comparison of 2 antibiotic combinations in 82 patients with severe gram-negative infections; transient, anicteric ALT elevations [&#x0003c;3 fold increased] occurred in 23% of carbenicillin, but only 3% of ticarcillin treated patients).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.nelson.1978.858">Nelson JD, Kusmiesz H, Shelton S, Woodman E. Clinical pharmacology and efficacy of ticarcillin in infants and children. <span><span class="ref-journal">Pediatrics. </span>1978;<span class="ref-vol">61</span>:858–63.</span> [<a href="/pubmed/673548" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 673548</span></a>]<div><i>(Among 98 children given ticarcillin iv or im, 3 had AST elevations to 50-81 U/L without jaundice and all values decreased during continued treatment).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.gonz_lez.1982.229">Gonz&#x000e1;lez MA. Comparison of the efficacy and safety of mezlocillin and ticarcillin in the treatment of patients with serious systemic infections. <span><span class="ref-journal">J Antimicrob Chemother. </span>1982;<span class="ref-vol">9</span> Suppl A:229–30.</span> [<a href="/pubmed/6210671" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6210671</span></a>]<div><i>(Randomized clinical trial of ticarcillin vs mezlocillin in 34 patients with severe infections; no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.graft.1982.497">Graft DF, Chesney PJ. Use of ticarcillin following carbenicillin-associated hepatotoxicity. <span><span class="ref-journal">J Pediatr. </span>1982;<span class="ref-vol">100</span>:497–9.</span> [<a href="/pubmed/7062188" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7062188</span></a>]<div><i>(Three patients with cystic fibrosis had elevations of ALT levels [to 54, 320 and 445 U/L] during iv carbenicillin therapy, minimally or not at all during subsequent iv ticarcillin therapy).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.parry.1982.273">Parry MF, Neu HC. The safety and tolerance of mezlocillin. <span><span class="ref-journal">J Antimicrob Chemother. </span>1982;<span class="ref-vol">9</span> Suppl A:273–80.</span> [<a href="/pubmed/6210679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6210679</span></a>]<div><i>(Analysis of 1148 patients given iv mezlocillin for 1-52 days; 3.7% had hypersensitivity reactions, 0.9% elevations in ALT, AST or Alk P, all were reversible and anicteric. In direct comparison, AST elevations occurred in 1.5% of mezlocillin vs 7.4% of ticarcillin recipients).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.ram_rezronda.1982.125">Ram&#x000ed;rez-Ronda CH, Guti&#x000e9;rrez J, Berm&#x000fa;dez RH. Comparative effectiveness, safety and tolerance of mezlocillin and ticarcillin: a prospective randomized trial. <span><span class="ref-journal">J Antimicrob Chemother. </span>1982;<span class="ref-vol">9</span> Suppl A:125–9.</span> [<a href="/pubmed/6210660" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6210660</span></a>]<div><i>(Randomized clinical trial comparing mezlocillin [n=21] and ticarcillin [n=20]; no ALT elevations mentioned).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.reed.1983.189">Reed WP, Palmer DL. Comparison of azlocillin and ticarcillin in the treatment of urinary tract infection. <span><span class="ref-journal">J Antimicrob Chemother. </span>1983;<span class="ref-vol">11</span> Suppl B:189–93.</span> [<a href="/pubmed/6619028" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6619028</span></a>]<div><i>(Randomized clinical trial of azlocillin vs ticarcillin in 35 patients with urinary tract infections, both were highly effective; no mention of ALT elevations or hepatic injury).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.jansen.1984.112">Jansen W, Schwarz A. Comparative evaluation of netilmicin-ticarcillin and tobramycin-ticarcillin in the treatment of serious systemic infections in elderly patients. <span><span class="ref-journal">Clin Ther. </span>1984;<span class="ref-vol">7</span>:112–20.</span> [<a href="/pubmed/6394127" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6394127</span></a>]<div><i>(Clinical trial in 60 patients with severe infections treated with ticarcillin combined with an aminoglycoside for 4-12 days; 92% efficacy, oto- and nephrotoxicity was attributed to tobramycin, no mention of hepatotoxicity or ALT elevations).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.van_der_auwera.1985.805">Van der Auwera P, Legrand JC. Ticarcillin-clavulanic acid therapy in severe infections. <span><span class="ref-journal">Drugs Exp Clin Res. </span>1985;<span class="ref-vol">11</span>:805–13.</span> [<a href="/pubmed/3836862" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3836862</span></a>]<div><i>(20 patients with severe infections received iv ticarcillin-clavulanate for 3 to 41 days; ALT elevations occurred in 3, but all were mild and self-limited).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.cone.1985.33">Cone LA, Woodard DR, Stoltzman DS, Byrd RG. Ceftazidime versus tobramycin-ticarcillin in the treatment of pneumonia and bacteremia. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>1985;<span class="ref-vol">28</span>:33–6.</span> [<a href="/pmc/articles/PMC176304/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC176304</span></a>] [<a href="/pubmed/3899005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3899005</span></a>]<div><i>(Randomized clinical trial of ceftazidime [n=128] vs tobramycin-ticarcillin [n=131] for severe infections; no mention of ALT elevations).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.mostow.1985.78">Mostow SR, O&#x02019;Brien RF. Safety and effectiveness of ticarcillin plus clavulanate potassium treatment of lower respiratory tract infections. <span><span class="ref-journal">Am J Med. </span>1985;<span class="ref-vol">79</span>:78–80.</span> [<a href="/pubmed/4073098" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4073098</span></a>]<div><i>(Description of 43 patients treated with ticarcillin-clavulanate; no mention of ALT elevations or liver toxicity).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.cox.1985.88">Cox CE. Comparative study of ticarcillin plus clavulanate potassium versus piperacillin in the treatment of hospitalized patients with urinary tract infections. <span><span class="ref-journal">Am J Med. </span>1985;<span class="ref-vol">79</span>:88–90.</span> [<a href="/pubmed/4073101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4073101</span></a>]<div><i>(Randomized clinical trial in hospitalized patients; 29% of ticarcillin-clavulanate vs 18% piperacillin recipients had laboratory adverse events, mostly ALT elevations, but specific numbers not given).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.gebhart.1985.101">Gebhart RJ, Duma RJ, Patterson PM. Timentin in the treatment of symptomatic complicated urinary tract infections in adult patients. <span><span class="ref-journal">Am J Med. </span>1985;<span class="ref-vol">79</span>:101–5.</span> [<a href="/pubmed/3852637" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3852637</span></a>]<div><i>(Use of iv ticarcillin-clavulanate in 34 patients with urinary tract infection; adverse events occurred in only one patient, no ALT elevations mentioned).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.pankey.1985.106">Pankey GA, Katner HP, Valainis GT, Clarkson MJ, Cortez LM, Dalovisio JR. Overview of bacterial infections of the skin and soft tissue and clinical experience with ticarcillin plus clavulanate potassium in their treatment. <span><span class="ref-journal">Am J Med. </span>1985;<span class="ref-vol">79</span>:106–15.</span> [<a href="/pubmed/4073076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4073076</span></a>]<div><i>(Trial in patients with severe skin infections found ALT elevations in 3 of 19 [16%] patients on ticarcillin-clavulanate, but none of 12 on cefazolin).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.roselle.1985.291">Roselle GA, Bode R, Hamilton B, Bibler M, Sullivan R, Douce R, Staneck JL. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>1985;<span class="ref-vol">27</span>:291–6.</span> [<a href="/pmc/articles/PMC176263/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC176263</span></a>] [<a href="/pubmed/3888101" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3888101</span></a>]<div><i>(43 patients given ticarcillin-clavulanate; 88% cure, 25% adverse events, but no mention of ALT elevations or liver injury).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.sanders.1985.96">Sanders CV, Marier RL, Aldridge KE, Derks FW, Martin DH. Safety and effectiveness of ticarcillin plus clavulanic acid in the treatment of community-acquired acute pyelonephritis in adult women. <span><span class="ref-journal">Am J Med. </span>1985;<span class="ref-vol">79</span>:96–100.</span> [<a href="/pubmed/3907345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3907345</span></a>]<div><i>(Use of ticarcillin-clavulanate had poor efficacy in pyelonephritis and 2 of 19 [10%] patients had AST elevations).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.ryan.1992.291">Ryan J, Dudley FJ. Cholestasis with ticarcillin-potassium clavulanate (Timentin). <span><span class="ref-journal">Med J Aust. </span>1992;<span class="ref-vol">156</span>:291.</span> [<a href="/pubmed/1738336" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1738336</span></a>]<div><i>(75 year old man developed jaundice 31 days after stopping a 9 day course of ticarcillin-clavulanate [bilirubin 8.1 mg/dL, ALT 448 U/L, Alk P 1330 U/L]; died of progressive lymphoma soon thereafter).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.sweet.1995.675">Sweet JM, Jones MP. Intrahepatic cholestasis due to ticarcillin-clavulanate. <span><span class="ref-journal">Am J Gastroenterol. </span>1995;<span class="ref-vol">90</span>:675–6.</span> [<a href="/pubmed/7717345" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7717345</span></a>]<div><i>(60 year old woman with neutropenic sepsis developed jaundice with 2 days of starting ticarcillin-clavulanate and gentamicin with bilirubin rising to 33 mg/dL, ALT 142 U/L, Alk P 355 U/L, improving on stopping antibiotics, but temporary worsening with restarting ticarcillin-clavulanate, then resolving in 1 month; the role of sepsis in causing the jaundice is suggested by the very short latency after starting ticarcillin-clavulanate).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.yellin.2007.367">Yellin AE, Johnson J, Higareda I, Congeni BL, Arrieta AC, Fernsler D, West J, et al.  Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. <span><span class="ref-journal">Am J Surg. </span>2007;<span class="ref-vol">194</span>:367–74.</span> [<a href="/pubmed/17693284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17693284</span></a>]<div><i>(Among 105 children in a controlled trial, ALT elevations occurred in 3% on ertapenem vs 4% on ticarcillin-clavulanate; no details given).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.chalasani.2008.1924">Chalasani N, Fontana RJ, Bonkovsky HL, Watkins PB, Davern T, Serrano J, Yang H, Rochon J., Drug Induced Liver Injury Network (DILIN).  Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. <span><span class="ref-journal">Gastroenterology. </span>2008;<span class="ref-vol">135</span>:1924–34.</span> [<a href="/pmc/articles/PMC3654244/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3654244</span></a>] [<a href="/pubmed/18955056" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18955056</span></a>]<div><i>(Among 300 cases of drug induced liver disease in the US collected from 2004 to 2008, none were attributed to ticarcillin or piperacillin).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.devarbhavi.2010.2396">Devarbhavi H, Dierkhising R, Kremers WK, Sandeep MS, Karanth D, Adarsh CK. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. <span><span class="ref-journal">Am J Gastroenterol. </span>2010;<span class="ref-vol">105</span>:2396–404.</span> [<a href="/pubmed/20648003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20648003</span></a>]<div><i>(313 cases of drug induced liver injury were seen over a 12 year period at a large hospital in Bangalore, India; none were attributed to extended spectrum, 4th generation penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contained 9036 hepatic adverse drug reactions in children, but ticarcillin and piperacillin were not listed in the top 41 causes).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, none of which were attributed to an extended spectrum penicillin).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, including 15 due to amoxicillin-clavulanate, 1 to dicloxacillin [2nd generation] and 1 to phenoxymethylpenicillin [1st generation], the latter two cases being anicteric; none were attributed to a 4th generation penicillin).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.sistanizad.2013.115">Sistanizad M, Peterson GM. Drug-induced liver injury in the Australian setting. <span><span class="ref-journal">J Clin Pharm Ther. </span>2013;<span class="ref-vol">38</span>:115–20.</span> [<a href="/pubmed/23350857" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23350857</span></a>]<div><i>(Among 17 persons with suspected drug induced liver injury seen over at 12 month period at a referral hospital in Tasmania, 11 were attributed to antibiotics including 4 to flucloxacillin, 2 amoxicillin with clavulanate, 2 amoxicillin, and 1 each to rifampin, moxifloxacin and ciprofloxacin; none to 4th generation penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.devarbhavi.2014.145">Devarbhavi H, Andrade RJ. Drug-induced liver injury due to antimicrobials, central nervous system agents, and nonsteroidal anti-inflammatory drugs. <span><span class="ref-journal">Semin Liver Dis. </span>2014;<span class="ref-vol">34</span>:145–61.</span> [<a href="/pubmed/24879980" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24879980</span></a>]<div><i>(Review of drug induced liver injury from various classes of agents, mentions that amoxicillin-clavulanate is the leading cause of drug induced liver injury, marked by a latency of several days to weeks, often after stopping the antibiotic, the injury varying from cholestatic to hepatocellular and the mortality rate being as high as 7%; no discussion of the 4th generation penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.bj_rnsson.2014.115">Bj&#x000f6;rnsson ES. Epidemiology and risk factors for idiosyncratic drug-induced liver injury. <span><span class="ref-journal">Semin Liver Dis. </span>2014;<span class="ref-vol">34</span>:115–22.</span> [<a href="/pubmed/24879977" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24879977</span></a>]<div><i>(Estimates of the incidence of drug induced liver injury have ranged from 2 to 19 case per 100,000 inhabitants, probably because of variation in medication use, definitions used and rigor of capturing all patients in a population; in recent studies, amoxicillin-clavulanate has been the most frequently implicated drug).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.kaye.2014.336">Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, et al.  Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study. <span><span class="ref-journal">Pharmacotherapy. </span>2014;<span class="ref-vol">34</span>:336–49.</span> [<a href="/pmc/articles/PMC4260122/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4260122</span></a>] [<a href="/pubmed/24865821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24865821</span></a>]<div><i>(In a US healthcare database with 1.3 million antimicrobial users, there were 607 cases of liver injury and 11 cases of liver failure, the highest relative risk for current single use being 3.2 for levofloxacin, 2.5 for amoxicillin-clavulanate, 2.5 for doxycycline, 2.3 for moxifloxacin and 2.3 for amoxicillin; no analysis of cases of other penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.fontana.2014.914">Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. <span><span class="ref-journal">Gastroenterology. </span>2014;<span class="ref-vol">146</span>:914–28.</span> [<a href="/pmc/articles/PMC4031195/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4031195</span></a>] [<a href="/pubmed/24389305" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24389305</span></a>]<div><i>(Review of clinical phenotypes and pathogenesis of different forms of drug induced liver injury including antibiotics and amoxicillin-clavulanate and flucloxacillin, but not of other penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.leise.2014.95">Leise MD, Poterucha JJ, Talwalkar JA. Drug-induced liver injury. <span><span class="ref-journal">Mayo Clin Proc. </span>2014;<span class="ref-vol">89</span>:95–106.</span> [<a href="/pubmed/24388027" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24388027</span></a>]<div><i>(Review of drug induced liver injury mentions that antibiotics are the most common cause and amoxicillin-clavulanate the most common single cause in Europe and the US, accounting for 8-22% of cases; no mention of other penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury from Latin American countries published between 1996 and 2012 identified 176 cases, of which 37 [19%] were attributed to antimicrobials, including one to benzathine penicillin and 3 to amoxicillin-clavulanate, but none to 4th generation penicillins such as piperacillin or ticarcillin).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 323 [36%] were attributed to antibiotics of which 106 [12%] were due to penicillins including one to a 1st, three to a 2nd [all due to oxacillin], 97 to a 3rd [91 to amoxicillin-clavulanate, and 6 to amoxicillin alone], and five to a 4th generation penicillin [all 5 to piperacillin-tazobactam]).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.gu_ant.2015.253">Gu&#x000e9;ant JL, Romano A, Cornejo-Garcia JA, Oussalah A, Chery C, Blanca-L&#x000f3;pez N, Gu&#x000e9;ant-Rodriguez RM, et al.  HLA-DRA variants predict penicillin allergy in genome-wide fine-mapping genotyping. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2015;<span class="ref-vol">135</span>:253–9.</span> [<a href="/pubmed/25224099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25224099</span></a>]<div><i>(In a genome wide association study of 387 patients with immediate allergic reactions to beta-lactam antibiotics, several class 2 HLA associations [HLA-DRA regions] were found for penicillin responses).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.bj_rnsson.2015.327">Bj&#x000f6;rnsson ES. Drug-induced liver injury: an overview over the most critical compounds. <span><span class="ref-journal">Arch Toxicol. </span>2015;<span class="ref-vol">89</span>:327–34.</span> [<a href="/pubmed/25618544" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25618544</span></a>]<div><i>(Review of the most common causes of drug induced liver injury in 3 recent surveys, all of which listed amoxicillin-clavulanate as the most frequent cause; none listed other penicillins).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.bj_rnsson.2016.224">Bj&#x000f6;rnsson ES. Hepatotoxicity by drugs: the most common implicated agents. <span><span class="ref-journal">Int J Mol Sci. </span>2016;<span class="ref-vol">17</span>:224.</span> [<a href="/pmc/articles/PMC4783956/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4783956</span></a>] [<a href="/pubmed/26861310" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26861310</span></a>]<div><i>(Review of the most common causes of drug induced liver injury based upon categorization from LiverTox, amoxicillin-clavulanate but no other penicillin was in the top category of causes [likelihood scores of A, with more than 100 cases published in the literature]).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.faulkner.2016.416">Faulkner L, Gibson A, Sullivan A, Tailor A, Usui T, Alfirevic A, Pirmohamed M, et al.  Detection of primary T cell responses to drugs and chemicals in HLA-typed volunteers: implications for the prediction of drug immunogenicity. <span><span class="ref-journal">Toxicol Sci. </span>2016;<span class="ref-vol">154</span>:416–29.</span> [<a href="/pubmed/27637899" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27637899</span></a>]<div><i>(Demonstration of T cell priming to drugs linked with specific class I HLA-alleles).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.nicoletti.2017.1078">Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, et al. International Drug-Induced Liver Injury Consortium, Drug-Induced Liver Injury Network Investigators, and International Serious Adverse Events Consortium.  Association of liver injury from specific drugs, or groups of drugs, with polymorphisms in HLA and other genes in a genome-wide association study. <span><span class="ref-journal">Gastroenterology. </span>2017;<span class="ref-vol">152</span>:1078–89.</span> [<a href="/pmc/articles/PMC5367948/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5367948</span></a>] [<a href="/pubmed/28043905" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28043905</span></a>]<div><i>(A genome wide association study done on 862 Caucasian patients with drug induced liver injury demonstrated a strong link with HLA-A*33:01 in those with cholestatic liver injury, particularly in cases attributed to terbinafine, fenofibrate and ticlopidine).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.blumenthal.2015.1288">Blumenthal KG, Youngster I, Rabideau DJ, Parker RA, Manning KS, Walensky RP, Nelson SB. Peripheral blood eosinophilia and hypersensitivity reactions among patients receiving outpatient parenteral antibiotics. <span><span class="ref-journal">J Allergy Clin Immunol. </span>2015;<span class="ref-vol">136</span>:1288–94.e1.</span> [<a href="/pmc/articles/PMC4640981/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4640981</span></a>] [<a href="/pubmed/25981739" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25981739</span></a>]<div><i>(Among 824 patients who underwent outpatient parenteral antibiotic therapy for at least 2 weeks, 210 [25%] developed eosinophilia including 58 of 207 [28%] who received &#x0201c;penicillins&#x0201d; of whom 3 developed signs of &#x0201c;possible&#x0201d; DRESS syndrome; specific penicillins accounting for the cases were not provided).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.tailor.2015.1310">Tailor A, Faulkner L, Naisbitt DJ, Park BK. The chemical, genetic and immunological basis of idiosyncratic drug-induced liver injury. <span><span class="ref-journal">Hum Exp Toxicol. </span>2015;<span class="ref-vol">34</span>:1310–7.</span> [<a href="/pubmed/26614821" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26614821</span></a>]<div><i>(Review of mechanisms of idiosyncratic drug induced liver injury focusing upon chemically reactive drug metabolites and genetic associations, particularly those with HLA alleles that implicate the adaptive immune response).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.meng.2016.1762">Meng X, Earnshaw CJ, Tailor A, Jenkins RE, Waddington JC, Whitaker P, French NS, et al.  Amoxicillin and clavulanate form chemically and immunologically distinct multiple haptenic structures in patients. <span><span class="ref-journal">Chem Res Toxicol. </span>2016;<span class="ref-vol">29</span>:1762–72.</span> [<a href="/pubmed/27603302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27603302</span></a>]<div><i>(Analysis of amoxicillin and clavulanate adducts produced in vitro and detected in vivo in patients with amoxicillin-clavulanate hepatotoxicity, the adducts were also present in culture median used to detect reactivity of specific T cell clones from patients).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.takeuchi.2018.1071">Takeuchi Y, Shinozaki T, Kumamaru H, Hiramatsu T, Matsuyama Y. Analyzing intent-to-treat and per-protocol effects on safety outcomes using a medical information database: an application to the risk assessment of antibiotic-induced liver injury. <span><span class="ref-journal">Expert Opin Drug Saf. </span>2018;<span class="ref-vol">17</span>:1071–9.</span> [<a href="/pubmed/30252549" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30252549</span></a>]<div><i>(Cohort matching of cases with vs without antibiotic therapy in a large electronic medical record database from the University of Tokyo Hospital from 2011 to 2015 with adjustments found rates of liver test abnormalities within 30 days of starting penicillins [25.2 per 1000] was higher than that of fluoroquinolones [11.4] and macrolide antibiotics [8.1] as well as controls [6.5 to 7.1]).</i></div></div></li><li><div class="bk_ref" id="TicarcillinClavulana.REF.cirulli.2019.1707">Cirulli ET, Nicoletti P, Abramson K, Andrade RJ, Bjornsson ES, Chalasani N, Fontana RJ, et al. Drug-Induced Liver Injury Network (DILIN) investigators.  International DILI consortium (iDILIC). A missense variant in PTPN22 is a risk factor for drug-induced liver injury. <span><span class="ref-journal">Gastroenterology. </span>2019;<span class="ref-vol">156</span>:1707–16.e2.</span> [<a href="/pmc/articles/PMC6511989/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6511989</span></a>] [<a href="/pubmed/30664875" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30664875</span></a>]<div><i>(Genome wide association studies on 2048 patients with drug induced liver injury and 12,439 controls identified a variant in PTPN22 which was highly associated with liver injury, allele frequency being 0.12 among cases and 0.08 among controls with highest association in Northern Europeans and in cases of amoxicillin clavulanate, PTPN22 being a cellular kinase involved in modulation of immune reactions).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK548183</span><span class="label">PMID: <a href="/pubmed/31643511" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643511</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Ticarcillin/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Ticlopidine/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK548183&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK548183/?report=reader">PubReader</a></li><li><a href="/books/NBK548183/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK548183" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK548183" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Ticarcillin-Clavulanate. [Updated 2020 Oct 20].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK548183/pdf/Bookshelf_NBK548183.pdf">PDF version of this page</a> (120K)</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=((ticarcillin/AE+AND+clavulanic+acid/AE)+OR+ticarcillin/AE)+AND+Human%5BMH%5D+AND+(%20drug-induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221995/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Ticarcillin-Clavulanate: from PubMed.gov</a></li><li><a href="https://clinicaltrials.gov/ct2/results?term=ticarcillin+clavulanate" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Ticarcillin-Clavulanate: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4866968" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4866968" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4866968" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2221864" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.</a><span class="source">[Antimicrob Agents Chemother. 1...]</span><div class="brieflinkpop offscreen_noflow">Beta-lactamase production and susceptibilities to amoxicillin, amoxicillin-clavulanate, ticarcillin, ticarcillin-clavulanate, cefoxitin, imipenem, and metronidazole of 320 non-Bacteroides fragilis Bacteroides isolates and 129 fusobacteria from 28 U.S. centers.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Appelbaum PC, Spangler SK, Jacobs MR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Antimicrob Agents Chemother. 1990 Aug; 34(8):1546-50. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/2228827" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.</a><span class="source">[J Antimicrob Chemother. 1990]</span><div class="brieflinkpop offscreen_noflow">Beta-lactamase production, beta-lactam sensitivity and resistance to synergy with clavulanate of 737 Bacteroides fragilis group organisms from thirty-three US centres.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Jacobs MR, Spangler SK, Appelbaum PC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Antimicrob Chemother. 1990 Sep; 26(3):361-70. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8693871" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.</a><span class="source">[Acta Clin Belg. 1996]</span><div class="brieflinkpop offscreen_noflow">In vitro activity of amoxycillin/clavulanate and ticarcillin/clavulanate compared with that of other antibiotics against anaerobic bacteria: comparison with the results of the 1987 survey.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pierard D, De Meyer A, Rosseel P, Van Cauwenbergh M, Struelens MJ, Delmee M, Goossens H, Claeys G, Glupczynski Y, Verbist L, et al. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Acta Clin Belg. 1996; 51(2):70-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/31643239" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillins (3rd Generation)</a><span class="source">[LiverTox: Clinical and Researc...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Penicillins (3rd Generation)<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/14726431" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.</a><span class="source">[J Antimicrob Chemother. 2004]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Augmentin (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an innovative antimicrobial agent.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">White AR, Kaye C, Poupard J, Pypstra R, Woodnutt G, Wynne B. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Antimicrob Chemother. 2004 Jan; 53 Suppl 1:i3-20. </em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643511" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643511" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=60469599a19b7255ae7c830b">Ticarcillin-Clavulanate - LiverTox</a><div class="ralinkpop offscreen_noflow">Ticarcillin-Clavulanate - LiverTox<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:22:35-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal106&amp;ncbi_phid=CE8D857504690BC100000000011D0056&amp;ncbi_session=CE8D857504695991_0285SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK548183%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK548183&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK548183/&amp;ncbi_pagename=Ticarcillin-Clavulanate - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8D857504695991_0285SID /projects/books/PBooks@9.2 portal106 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>